On October 27, 2017, in U.S. ex rel. Ibanez v. Bristol-Myers Squibb Co., 874 F.3d 905 (6th Cir. 2017) (Ibanez), the Sixth Circuit Court of Appeals affirmed the dismissal of a qui tam action under the False Claims Act (FCA) alleging that Bristol-Myers Squibb engaged in a nationwide scheme to promote off-label uses of its anti-psychotic drug Abilify. In its decision, the Sixth Circuit highlights the challenges for a relator asserting FCA claims based on off-label promotion in a manner that…
Continue reading...
Litigation
Continue reading...
- High Court Denies Bid to Review Neurontin RICO Rulings (subscription required)
- Merck Settles Fosamax Jaw-Injury Claims for $28M (subscription required)
- Boehringer Fined $1M For Withholding Docs in MDL (subscription required)
- Expert Testimony Must be Backed By Science, Pa. Court Rules (subscription required)
- High Court Passes on Lupron Labeling Suit (subscription required)
- 1st Circ. Ends Takeda FCA Suit But Limits Scope of Ruling (subscription required)
- Medtronic Escapes Jury’s $18M Surgical Fire Verdict (subscription required)
- J&J Keeps Vaginal Mesh Suit Out of
Continue reading...